This site is intended for Healthcare Professionals only.

Retrospective concessionary price for Isocarboxazid 10mg tablets

Date:

Share post:

The Department of Health and Social Care have retrospectively granted a concessionary price for Isocarboxazid 10mg tablets for the months of May and June 2021.

While the reimbursement price had previously been £217.75, a concessionary price of £249.10 has now been granted.

The NHS Business Services Authority confirmed that payment for the difference – £31.35 for every pack of 56 claimed – will be adjusted accordingly for the mentioned time period where contractors have submitted claims in those months. This adjustment will be paid on 31 December 2021 in the next Schedule of Payments.

The PSNC added that it sought the pricing adjustment for the tablets as the product did not fulfil Category A criteria in the May and June 2021 Drug Tariffs.

For the month of July 2021, a price concession was granted for Isocarboxazid 10mg tablets (56) at £249.10 and in August 2021 the product was moved to Category C based on Alliance Pharmaceuticals Ltd list price £249.10.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

[my_vc_php_output]

Related articles

Boots pharmacy closures in Hampton leave vulnerable residents struggling – Munira Wilson MP tells Parliament

She pointed out that a major factor driving pharmacy closures is a significant real-term reduction in pharmacy funding   Munira Wilson,...

Prof Mahendra Patel leads innovative research study: Community pharmacies to address health disparities

The research study is set to utilise community pharmacies and pharmacy technicians to recruit participants and gather crucial...

Rosehill Pharmacy gets a makeover under new leadership

Rosehill Pharmacy in Sutton has recently undergone a significant transformation with its acquisition by Arun Kanagaratnam, who took...

Drug shortage: Kay-Cee-L syrup to be out of stock from late September

Healthcare providers are advised to prioritise remaining supplies of Kay-Cee-L syrup for patients requiring doses of less than...